Changes in Skeletal Muscle Atrophy over Time in a Rat Model of Adenine-Induced Chronic Kidney Disease
Source abstract
Abstract
This study evaluated changes over time in skeletal muscle atrophy, expressions of skeletal muscle anabolic and catabolic genes, and mitochondrial activity by skeletal muscle type in an adenine-induced chronic kidney disease (CKD) model. A CKD model was successfully established by feeding male Wistar rats a 0.75% adenine diet for 4 weeks starting at 8 weeks of age. Control and CKD groups were sacrificed at 12 and 20 weeks of age. The back muscles were analyzed histologically, and succinate dehydrogenase (SDH) staining was performed to evaluate mitochondrial activity. Gene expressions of myogenic determination gene number 1 and myogenin as indicators of muscle anabolism, atrogin-1 and muscle RING-finger protein-1 (MuRF1) as indicators of muscle catabolism, and peroxisome proliferator-activated receptor-γ coactivator-1-α as a marker of mitochondrial biogenesis were assessed. Type I and type II muscle cross-sectional areas (CSAs) were decreased at 12 weeks, but type I muscle CSA was recovered at 20 weeks. SDH staining was lower in CKD than in control rats at 12 weeks, but no significant difference was observed at 20 weeks. Increased expressions of myogenin, atrogin-1, and MuRF-1 were observed only at 12 weeks, but no differences were observed at 20 weeks. The adenine-induced CKD rat model appears to show changes in muscle atrophy over time.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Adipose Tissue and Metabolism · Muscle metabolism and nutrition · Diet and metabolism studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
Department of Rehabilitation Medicine, Akita University Hospital, 1-1-1 Hondo, Akita 010-8543, Japan
References (37)
Show source-provided references
1. Chronic kidney disease as a global public health problem: Approaches and initiatives—A position statement from Kidney Disease Improving Global Outcomes10.1038/sj.ki.5002343 ↗
2. Prevalence and Disease Burden of Chronic Kidney Disease10.1007/978-981-13-8871-2_1 ↗
3. Vascular calcification in chronic kidney disease: Role of disordered mineral metabolism10.2174/1381612820666140212194926 ↗
4. Cheng, T.C., and Huang, S.H. (2022). Muscle Wasting in Chronic Kidney Disease: Mechanism and Clinical Implications—A Narrative Review. Int. J. Mol. Sci., 23.10.3390/ijms23116047 ↗
5. Physical activity and mortality in chronic kidney disease (NHANES III)10.2215/CJN.01970309 ↗
6. Watson, E.L., and Viana, J.L. (2017). The Effect of Resistance Exercise on Inflammatory and Myogenic Markers in Patients with Chronic Kidney Disease. Front. Physiol., 8.10.3389/fphys.2017.00541 ↗
7. Avin, K.G., and Chen, N.X. (2016). Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease. PLoS ONE, 11.10.1371/journal.pone.0159411 ↗
8. Serrano, E., and Whitaker-Menezes, D. (2022). Uremic Myopathy and Mitochondrial Dysfunction in Kidney Disease. Int. J. Mol. Sci., 23.10.3390/ijms232113515 ↗
9. Influence of different stages of experimental chronic kidney disease on rats locomotor and postural skeletal muscles microcirculation10.1080/08860220801985694 ↗
10. Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease
11. miRNA-23a/27a attenuates muscle atrophy and renal fibrosis through muscle-kidney crosstalk10.1002/jcsm.12296 ↗
12. Diabetic mice exhibited a peculiar alteration in body composition with exaggerated ectopic fat deposition after muscle injury due to anomalous cell differentiation10.1002/jcsm.12044 ↗
13. Sato, E., and Mori, T. (2016). Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci. Rep., 6.10.1038/srep36618 ↗
14. Obesity causes renal mitochondrial dysfunction and energy imbalance and accelerates chronic kidney disease in mice10.1152/ajprenal.00203.2019 ↗
15. Skeletal myopathy in CKD: A comparison of adenine-induced nephropathy and 5/6 nephrectomy models in mice10.1152/ajprenal.00117.2021 ↗
16. Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling10.7554/eLife.74782 ↗
17. Aerobic Exercise Attenuates Kidney Injury, Improves Physical Performance, and Increases Antioxidant Defenses in Lungs of Adenine-Induced Chronic Kidney Disease Mice10.1007/s10753-022-01643-y ↗
18. Effects of eldecalcitol on bone and skeletal muscles in glucocorticoid-treated rats10.1007/s00774-015-0664-4 ↗
19. Animal model of adenine-induced chronic renal failure in rats10.1159/000183992 ↗
20. Fontecha-Barriuso, M., and Martin-Sanchez, D. (2020). The Role of PGC-1α and Mitochondrial Biogenesis in Kidney Diseases. Biomolecules, 10.10.3390/biom10020347 ↗
21. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics10.1038/bmt.2012.244 ↗
22. Mechanisms for fiber-type specificity of skeletal muscle atrophy10.1097/MCO.0b013e328360272d ↗
23. Muscle type and fiber type specificity in muscle wasting10.1016/j.biocel.2013.05.016 ↗
24. Atrophy of non-locomotor muscle in patients with end-stage renal failure10.1093/ndt/gfg325 ↗
25. Morphometric analysis of muscle fibre types in rat locomotor and postural skeletal muscles in different stages of chronic kidney disease
26. The myogenic regulatory factors, determinants of muscle development, cell identity and regeneration10.1016/j.semcdb.2017.11.010 ↗
27. Reduced differentiation potential of primary MyoD-/- myogenic cells derived from adult skeletal muscle10.1083/jcb.144.4.631 ↗
28. Function of the myogenic regulatory factors Myf5, MyoD, Myogenin and MRF4 in skeletal muscle, satellite cells and regenerative myogenesis10.1016/j.semcdb.2017.11.011 ↗
29. Myogenin promotes myocyte fusion to balance fibre number and size10.1038/s41467-018-06583-6 ↗
30. Enoki, Y., and Watanabe, H. (2016). Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci. Rep., 6.10.1038/srep32084 ↗
31. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction10.1002/jcsm.12202 ↗
32. Alcalde-Estévez, E., and Sosa, P. (2021). Uraemic toxins impair skeletal muscle regeneration by inhibiting myoblast proliferation, reducing myogenic differentiation, and promoting muscular fibrosis. Sci. Rep., 11.10.1038/s41598-020-79186-1 ↗
33. Takemura, K., and Nishi, H. (2020). Mitochondrial Dysfunction in Kidney Disease and Uremic Sarcopenia. Front. Physiol., 11.10.3389/fphys.2020.565023 ↗
34. Chronic kidney disease reduces muscle mitochondria and exercise endurance and its exacerbation by dietary protein through inactivation of pyruvate dehydrogenase10.1038/ki.2013.473 ↗
35. Differentiation of the intracellular structure of slow- versus fast-twitch muscle fibers through evaluation of the dielectric properties of tissue10.1088/0031-9155/59/10/2369 ↗
36. Hayeeawaema, F., and Muangnil, P. (2023). A novel model of adenine-induced chronic kidney disease-associated gastrointestinal dysfunction in mice: The gut-kidney axis. Saudi J. Biol. Sci., 30.10.1016/j.sjbs.2023.103660 ↗
37. Analysis of bone in adenine-induced chronic kidney disease model rats10.1016/j.afos.2021.11.001 ↗